ToxStrategies Merges with Clintrex Research to Strengthen Pharmaceutical Expertise

ToxStrategies has acquired Clintrex Research Corporation, enhancing its scientific consulting services for pharmaceutical clients. This partnership brings together two industry leaders, with Clintrex's expertise in clinical and regulatory development for central nervous system diseases complementing ToxStrategies' existing offerings. Drs. Olanow and Kieburtz will lead Clintrex as a Division of ToxStrategies, aiming to optimize biopharmaceutical cold chain and accelerate drug development.

ToxStrategies, a renowned scientific consulting firm, has recently announced the acquisition of Clintrex Research Corporation, a clinical research company specializing in central nervous system (CNS) diseases [1]. This strategic move aims to enhance ToxStrategies' existing offerings and further solidify its position as a trusted partner for pharmaceutical companies.

Clintrex, with its extensive experience in clinical and regulatory development for CNS diseases, complements ToxStrategies' existing expertise in toxicology, pharmacology, and regulatory affairs. The company's international team of experts works closely with pharmaceutical organizations to identify, clarify, and solve pre-clinical, clinical trial, biostatistical, and regulatory issues essential to product development and approval [1].

Dr. Olanow and Dr. Kieburtz, the leading figures at Clintrex, will now lead the division as part of ToxStrategies. Their expertise in CNS diseases, particularly neurodegenerative disorders like Alzheimer's, Parkinson's, Huntington's, and multiple sclerosis, will prove invaluable in accelerating drug development processes and optimizing biopharmaceutical cold chains [1].

ToxStrategies' acquisition of Clintrex demonstrates its commitment to providing practical, effective, and efficient solutions to pharmaceutical companies facing regulatory and clinical challenges. With over 150 pharmaceutical and biotech companies engaging with Clintrex for its advisory services and assistance in developing new therapies for CNS disorders, this strategic move is expected to significantly expand ToxStrategies' client base and enhance its reputation as a leading scientific consulting firm [1].

References:
[1] ToxStrategies. (2023, January 24). ToxStrategies Acquires Clintrex Research Corporation to Enhance Scientific Consulting Services for Pharmaceutical Clients. Retrieved from https://www.toxstrategies.com/press-releases/press-release-details/2023/ToxStrategies-Acquires-Clintrex-Research-Corporation-to-Enhance-Scientific-Consulting-Services-for-Pharmaceutical-Clients/default.aspx